Citations

Clear

1792 citation(s) found for "Stephanie".

Structural and functional analyses reveal promiscuous and species specific use of ephrin receptors by Cedar virus
Laing, Eric D. , Navaratnarajah, Chanakha K. , Silva, Sofia Cheliout Da, Petzing, Stephanie R., Xu, Yan , Sterling, Spencer L. , Wang, Lin‐Fa , Amaya, Moushimi , Nikolov, Dimitar B. , Cattaneo, Roberto , Broder, Christopher C. , Xu, Kai , Wang, Lin-Fa , Cattaneo, Roberto , Broder, Christopher C , Xu, Kai , Xu, Yan, Marsh, Glenn A.

Mayo Clinic

Proceedings of the National Academy of Sciences | September 23, 2019 | Volume: 116 | Issue: 41 | Pages: 20707-20715

10.1073/pnas.1911773116 | PMID 31548390 Get It

Cedar virus (CedV) is a bat-borne henipavirus related to Nipah virus (NiV) and Hendra virus (HeV), zoonotic agents of fatal human disease. CedV receptor-binding protein (G) shares only ∼30% sequence identity with those of NiV and HeV, although they can all use ephrin-B2 as an entry receptor. We demonstrate that CedV also enters cells through additional B- and A-class ephrins (ephrin-B1, ephrin-A2, and ephrin-A5) and report the crystal structure of the CedV G ectodomain alone and in complex with ephrin-B1 or ephrin-B2. The CedV G receptor-binding site is structurally distinct from other henipaviruses, underlying its capability to accommodate additional ephrin receptors. We also show that CedV can enter cells through mouse ephrin-A1 but not human ephrin-A1, which differ by 1 residue in the key contact region. This is evidence of species specific ephrin receptor usage by a henipavirus, and implicates additional ephrin receptors in potential zoonotic transmission.
Exclusive use of PowerFlow ports may not be appropriate for all patients
Boshell, Michael N., Adamski, Jill , Pham, Huy P. , Guillory, Bryan, Sikora, James , Lisby, Stephanie, Lovingood, Ashley, Zheng, Xuemei , Williams, Lance A , Pham, Huy P , Marques, Marisa B.

Mayo Clinic

Journal of Clinical Apheresis | September 18, 2019 | Volume: 35 | Issue: 1 | Pages: 66-68

10.1002/jca.21749 | PMID 31532839 Get It

Dilution of Molecular–Pathologic Gene Signatures by Medically Associated Factors Might Prevent Prediction of Resection Status After Debulking Surgery in Patients With Advanced Ovarian Cancer
Kommoss, Stefan , Tourani, Roshan , Grandelis, Anthony , Uppendahl, Locke , Aliferis, Constantin , Burges, Alexander , Wang, Chen , Canzler, Ulrich , Belau, Antje , Prader, Sonia , Hanker, Lars , Ma, Sisi , Hilpert, Felix , Schneider, Stephanie , Kimmig, Rainer , Kurzeder, Christian , Schmalfeldt, Barbara , Braicu, Elena Ioana , Harter, Philipp , Dowdy, Sean C. , Winterhoff, Boris , Pfisterer, Jacobus , Uppendahl, Locke , Burges, Alexander , Wang, Chen , Heitz, Florian , Ma, Sisi , Ataseven, Beyhan , Sehouli, Jalid , Bois, Andreas du

Mayo Clinic

Clinical Cancer Research | September 16, 2019 | Volume: 26 | Issue: 1 | Pages: 213-219

10.1158/1078-0432.ccr-19-1741 | PMID 31527166 Get It

Abstract Purpose: Predicting surgical outcome could improve individualizing treatment strategies for patients with advanced ovarian cancer. It has been suggested earlier that gene expression signatures (GES) might harbor the potential to predict surgical outcome. Experimental Design: Data derived from high-grade serous tumor tissue of FIGO stage IIIC/IV patients of AGO-OVAR11 trial were used to generate a transcriptome profiling. Previously identified molecular signatures were tested. A theoretical model was implemented to evaluate the impact of medically associated factors for residual disease (RD) on the performance of GES that predicts RD status. Results: A total of 266 patients met inclusion criteria, of those, 39.1% underwent complete resection. Previously reported GES did not predict RD in this cohort. Similarly, The Cancer Genome Atlas molecular subtypes, an independent de novo signature and the total gene expression dataset using all 21,000 genes were not able to predict RD status. Medical reasons for RD were identified as potential limiting factors that impact the ability to use GES to predict RD. In a center with high complete resection rates, a GES which would perfectly predict tumor biological RD would have a performance of only AUC 0.83, due to reasons other than tumor biology. Conclusions: Previously identified GES cannot be generalized. Medically associated factors for RD may be the main obstacle to predict surgical outcome in an all-comer population of patients with advanced ovarian cancer. If biomarkers derived from tumor tissue are used to predict outcome of patients with cancer, selection bias should be focused on to prevent overestimation of the power of such a biomarker. See related commentary by Handley and Sood, p. 9
Spinal Cord Injury Results in Chronic Mechanical Stiffening
Cooper, John G. , Sicard, Delphine , Sharma, Sripadh , Gulden, Stephanie Van, McGuire, Tammy L., Pareja‐Cajiao, Miguel , Tschumperlin, Daniel J. , Cajiao, Miguel Pareja, Kessler, John A.

Mayo Clinic

Journal of Neurotrauma | September 13, 2019 | Volume: 37 | Issue: 3 | Pages: 494-506

10.1089/neu.2019.6540 | PMID 31516087 Get It

Gliosis and fibrosis after spinal cord injury (SCI) lead to formation of a scar that is thought to present both molecular and mechanical barriers to neuronal regeneration. The scar consists of a meshwork of reactive glia and deposited, cross-linked, extracellular matrix (ECM) that has long been assumed to present a mechanically “stiff” blockade. However, remarkably little quantitative information is available about the rheological properties of chronically injured spinal tissue. In this study we utilize atomic force microscopy microindentation to provide quantitative evidence of chronic mechanical stiffening after SCI. Using the results of this tissue characterization, we assessed the sensitivity of both mouse and human astrocytes in vitro and determined that they are exquisitely mechanosensitive within the relevant range of substrate stiffness observed in the injured/uninjured spinal cord. We then utilized a novel immune modifying nanoparticle (IMP) treatment as a tool to reveal fibrotic scarring as one of the key drivers of mechanical stiffening after SCI in vivo . We also demonstrate that glial scar-forming astrocytes form a highly aligned, anisotropic network of glial fibers after SCI, and that IMP treatment mitigates this pathological alignment. Taken together, our results identify chronic mechanical stiffening as a critically important aspect of the complex lesion milieu after SCI that must be considered when assessing and developing potential clinical interventions for SCI.
Statin therapy: does sex matter?
Kapoor, Ekta , Moyer, Ann M. , Hodis, Howard N., Miller, Virginia M. , Faubion, Stephanie S. , Kapoor, Ekta

Mayo Clinic

Menopause | September 11, 2019 | Volume: 26 | Issue: 12 | Pages: 1425-1435

10.1097/gme.0000000000001412 | PMID 31513091 Get It

Abstract Objective: Statins are a class of drugs that competitively bind to the active site of HMG-CoA reductase enzyme, thereby inhibiting the initial steps in cholesterol synthesis. Originally approved for use in lowering serum cholesterol, a risk factor for developing atherosclerosis and coronary heart disease, statins have subsequently been noted to have myriad extrahepatic effects, including potential effects on cognition, diabetes, breast cancer, bone, and muscle. This narrative review assesses the current state of the science regarding the risks and benefits of statin therapy in women to identify areas where additional research is needed. Methods: Basic and clinical studies were identified by searching PubMed with particular attention to inclusion of female animals, women, randomized controlled trials, and sex-specific analyses. Results: Statin therapy is generally recommended to reduce the risk of cardiovascular disease. None of the current clinical guidelines, however, offer sex-specific recommendations for women due to lack of understanding of sex differences and underlying mechanisms of disease processes. In addition, conclusions regarding efficacy of treatments do not consider lipid solubility for the drug, dosing, duration of treatment, interactions with estrogen, or comorbidities. Pleiotropic effects of statins are often derived from secondary analysis of studies with cardiovascular events as primary outcomes. Conclusions: Many of the trials that have established the efficacy and safety of statins were conducted predominantly or entirely in men, with results extrapolated to women. Additional research is needed to guide clinical recommendations specific to women. Video Summary: http://links.lww.com/MENO/A462.
Team Approach: Role of Medical and Surgical Management in Rheumatoid Arthritis of the Hand and Wrist
O’Shaughnessy, Maureen , Kannas, Stephanie , Ernste, Floranne C. , Rizzo, Marco , O'Shaughnessy, Maureen A, Ernste, Floranne

Mayo Clinic

JBJS Reviews | August 28, 2019 | Volume: 7 | Issue: 8 | Pages: e10-e10

10.2106/jbjs.rvw.18.00196 | PMID 31460989 Get It

» Treatment of the patient with rheumatoid arthritis affecting the hand and wrist can be a challenging endeavor. Optimal management for best outcomes includes careful collaboration between providers managing the medical treatment of the disease, therapists, hand surgeons, and the patient. » In this review, we present a challenging clinical scenario with input from key voices from various medical fields to provide a balanced and unbiased diagnosis and treatment recommendation for a patient with complex rheumatoid pathology affecting her hand and wrist.
Multi‐institutional analysis of outcomes following transoral surgery for HPV‐positive oropharyngeal squamous cell carcinoma in elderly patients
Jackson, Ryan S. , Chen, Stephanie , Last, Aisling, Khan, Amish M., Kallogjeri, Dorina , Abel, Kathryn M. Van , Moore, Eric J. , Pipkorn, Patrik , Van Abel, Kathryn M

Mayo Clinic

Head & Neck | August 28, 2019 | Volume: 41 | Issue: 11 | Pages: 3933-3939

10.1002/hed.25946 | PMID 31460691 Get It

AbstractBackgroundThe incidence of human papillomavirus (HPV)‐related oropharyngeal squamous cell carcinoma (OPSCC) is rising, even in elderly patients. The outcomes of transoral surgery (TOS) in this population are not entirely known.MethodsA retrospective review was performed at two institutions from October 2003 to September 2016 on patients 70 years or older with HPV‐related OPSCC treated with TOS.ResultsA total of 75 patients were included with a mean age of 74 years (70‐87 years). At a median follow‐up of 35.7 months, 3‐year overall survival was 81.5% and disease‐specific survival was 94.3%. Advanced cT stage (odds ratio, 2.74; 95% confidence interval, 1.13‐6.64) negatively impacted OS. Conjunctive consolidation was performed to create a staging system with patients older than 80 years, severe comorbidity, and cT3‐4 having worse survival.ConclusionsElderly patients with HPV‐related OPSCC treated with TOS have excellent survival and therefore should not be excluded from such therapy based on age alone.
Genetic overlap between autoimmune diseases and non‐Hodgkin lymphoma subtypes
Din, Lennox, Kosaraju, Nikitha , Smedby, Karin E. , Berndt, Sonja I. , Skibola, Christine F., Nieters, Alexandra, Wang, Sophia , McKay, James , Cocco, Pierluigi , Foretová, Lenka , Staines, Anthony , Mack, Thomas M. , Sanjosé, Sílvia de , Vyse, Timothy J. , Padyukov, Leonid , Monnereau, Alain , Arslan, Alan A. , Moore, Amy , Brooks‐Wilson, Angela , Novak, Anne J. , Glimelius, Bengt , Birmann, Brenda M. , Link, Brian K. , Stewart, Carolyn, Vajdic, Claire M. , Magnani, Corrado , Conti, David V. , Cox, David G. , Casabonne, Delphine, Kane, Eleanor , Roman, Eve , Salles, Gilles , Adami, Hans‐Olov , Ghesquières, Hervé , Vivo, Immaculata De , Clavel, Jacqueline , Spinelli, John J., Curtin, Karen , Costenbader, Karen H. , Onel, Kenan , Offit, Kenneth , Morton, Lindsay M. , Conde, Lucía , Miligi, Lucia , Melbye, Mads , Liebow, Mark , Purdue, Mark P. , Glenn, Martha, Din, M. Azhar Ud, Rothman, Nathaniel , Camp, Nicola J. , Doo, Nicole Wong , Becker, Nikolaus, Pradhan, Nisha , Bracci, Paige M. , Vineis, Paolo , Brennan, Paul , Kraft, Peter , Lan, Qing , Severson, Richard K., Vermeulen, Roel , Kaaks, Rudolph, Travis, Ruth C. , Weinstein, Stephanie J. , Ansell, Stephen M. , Zheng, Tongzhang, Benavente, Yolanda , Taub, Zachary, Madireddy, Lohith, Gourraud, Pierre‐Antoine , Oksenberg, Jorge R. , Hjalgrim, Henrik , Khankhanian, Pouya , Cerhan, James R , Khankhanian, Pouya , Link, Brian K , Cocco, Pierluigi , Brooks-Wilson, Angela R , Vajdic, Claire M , Kane, Eleanor , Arslan, Alan A , Travis, Ruth C , De Vivo, Immaculata , Kraft, Peter , Morton, Lindsay M , Padyukov, Leonid , Salles, Gilles A , Wang, Sophia S , Birmann, Brenda M , Roman, Eve , Clavel, Jacqueline , Conti, David V , Doo, Nicole Wong , Sheikh, Mohammad, Bernatsky, Sasha , Maynadié, Marc , Haïoun, Corinne , Casabonne, Delphine , Albanes, Demetrius , Muzi, Giacomo , Giles, Graham G. , Cerhan, James R. , Hofmann, Jonathan N. , Vijai, Joseph , Teras, Lauren R. , Ennas, Maria Grazia , Southey, Melissa C. , Boffetta, Paolo , Milne, Roger L. , Chanock, Stephen Jacob , Slager, Susan L. , Zhang, Yawei , Cozen, Wendy

Mayo Clinic

Genetic Epidemiology | August 13, 2019 | Volume: 43 | Issue: 7 | Pages: 844-863

10.1002/gepi.22242 | PMID 31407831 Get It

AbstractEpidemiologic studies show an increased risk of non‐Hodgkin lymphoma (NHL) in patients with autoimmune disease (AD), due to a combination of shared environmental factors and/or genetic factors, or a causative cascade: chronic inflammation/antigen‐stimulation in one disease leads to another. Here we assess shared genetic risk in genome‐wide‐association‐studies (GWAS).Secondary analysis of GWAS of NHL subtypes (chronic lymphocytic leukemia, diffuse large B‐cell lymphoma, follicular lymphoma, and marginal zone lymphoma) and ADs (rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis). Shared genetic risk was assessed by (a) description of regional genetic of overlap, (b) polygenic risk score (PRS), (c)"diseasome", (d)meta‐analysis.Descriptive analysis revealed few shared genetic factors between each AD and each NHL subtype. The PRS of ADs were not increased in NHL patients (nor vice versa). In the diseasome, NHLs shared more genetic etiology with ADs than solid cancers (p = .0041). A meta‐analysis (combing AD with NHL) implicated genes of apoptosis and telomere length.This GWAS‐based analysis four NHL subtypes and three ADs revealed few weakly‐associated shared loci, explaining little total risk. This suggests common genetic variation, as assessed by GWAS in these sample sizes, may not be the primary explanation for the link between these ADs and NHLs.
RADI-04. PRETREATMENT VOLUME OF MRI-DETERMINED WHITE MATTER INJURY (WMI) PREDICTS COGNITIVE DECLINE AFTER HIPPOCAMPAL AVOIDANT (HA) WBRT FOR BRAIN METASTASES: SECONDARY ANALYSIS OF NRG ONCOLOGY RTOG 0933
Bovi, Joseph , Pugh, Stephanie L. , Sabesevitz, David, Paulson, E.S. , Gondi, Vinai , Pinover, Wayne H., Chao, Samuel T. , Machtay, Mitchell , DeNittis, Albert S., Laack, Nadia, Greenspoon, Jeffrey , Mannel, Robert S., Dominello, M.M., Kachnic, Lisa A. , Robinson, Clifford G. , Mehta, Minesh P. , Kundapur, Vijayananda , Huang, Jiayi

Mayo Clinic

Neuro-Oncology Advances | August 12, 2019 | Volume: 1 | Issue: Supplement_1 | Pages: i22-i22

10.1093/noajnl/vdz014.097 Get It

Abstract PURPOSE: RTOG 0933 demonstrated benefits to memory following HA-WBRT, supporting the hypothesis of hippocampal radiosensitivity and associated memory specificity. However, some patients demonstrated cognitive decline, suggesting mechanisms outside hippocampal radiosensitivity playing a role. WMI has been implicated in RT-induced cognitive decline. This secondary analysis explored the relationship between pre-treatment WMI and memory following HA-WBRT. METHODS AND MATERIALS: 113 patients received HA-WBRT. Standardized cognitive assessments were performed at baseline, 2, 4, and 6 months. The primary endpoint was Hopkins Verbal Learning Test Delayed Recall (HVLT-DR) at 4 mos. Secondary endpoints included HVLT Total Recall (HVLT-TR) and Recognition (HVLT-Recog). Of 113 patients, 34 underwent pre-treatment and 4-month post-treatment HVLT testing and pre-treatment post-contrast volumetric T1 and axial T2/FLAIR MRI. Volumetric analysis of metastatic disease burden and disease-unrelated WMI was conducted on the pre-treatment MRI. Correlational analyses were performed examining the relationship between pre-treatment WMI and HVLT outcomes following HA-WBRT. RESULTS: Correlation was found between larger volumes of pre-treatment WMI and decline in HVLT-Recog (r=.54, p< .05) and a correlational trend was observed between larger volume of pre-treatment WMI and decline in HVLT-DR (r=.31, p=.08). Patients with higher pre-treatment disease burden experienced a greater magnitude of stability or positive shift in HVLT-recall and –delayed recall following HA-WBRT. (r=-.36 and r=-.36, p’s < .05), compared to the magnitude of stability/positive shift in those with lesser disease burden. CONCLUSION: In patients receiving HA-WBRT, pre-treatment-WMI predicts memory decline, suggesting white matter integrity pre-treatment contributes to the pathogenesis of post-WBRT cognitive toxicity independent of hippocampal stem cell radiosensitivity. Less decline or improvement in HVLT following HA-WBRT for patients with higher pre-treatment intracranial metastatic burden supports the importance of WBRT-induced intracranial control on cognition. These imaging biomarkers for cognitive toxicity will be further explored on NRG CC001 and CC003, phase III trials of WBRT with or without HA.
Abstract 873: Molecular mechanisms of non-small cell lung cancer growth and drug resistance
Astone, Matteo , Liu, Ping , Coyle, Abbygail M. , Dankert, Erin N. , Hoffman, Dane K. , Hall, Stephanie R., Kuang, Rui , Roden, Anja C. , Alam, Sk. Kayum , Wang, Li , Zhang, Wei , Mansfield, Aaron S. , Hoeppner, Luke H.

Mayo Clinic

Cancer Research | August 7, 2019 | Volume: 79 | Issue: 13_Supplement | Pages: 873-873

10.1158/1538-7445.am2019-873 Get It

Abstract Lung cancer is the deadliest and most frequently diagnosed type of tumor worldwide, with 1.6 million deaths reported annually. Non-small cell lung cancer (NSCLC) represents 85% of all lung cancer cases and carries a poor 5-year survival rate below 15%. Prognoses remain dismal due to the large number of patients diagnosed with advanced stage disease and the development of resistance to current therapies. A better understanding of acquired drug resistance will help to circumvent the progression of lung cancer and make significant strides in improving NSCLC patient treatment. Our recent work demonstrates that dopamine and cAMP-regulated phosphoprotein, Mr 32000 (DARPP-32) and its amino-terminally truncated splice variant (t-DARPP) promote lung tumor growth in orthotopic mouse models. IHC staining of 62 human lung adenocarcinoma tissues showed that t-DARPP expression is elevated with increasing tumor (T) staging score, which represents the size of the primary tumor and whether it has grown into nearby areas, as a metric of tumor progression and growth. Correspondingly, a computational biology analysis of 513 lung adenocarcinoma patients revealed upregulation of t-DARPP isoform expression correlates with advanced T stage and is associated with poor overall survival. We identified a novel physical interaction between DARPP-32 and inhibitory kappa B kinase-α (IKKα) that promotes NSCLC cell migration through activation of non-canonical NF-κB2 signaling. It has been shown that DARPP-32 overexpression inhibits gefitinib-induced apoptosis in gastric cancer and t-DARPP contributes to the trastuzumab resistance phenotype in breast cancer. Our recent findings suggest DARPP-32 and t-DARPP overexpression in NSCLC promotes resistance to specific molecular targeted inhibitors by enabling tumor cells to evade apoptosis via Akt- and Erk-dependent cell survival mechanisms. Current ongoing studies are focused on manipulating expression of DARPP-32 isoforms in lung tumor cells to prevent resistance to targeted therapies in NSCLC patients. Citation Format: SK Kayum Alam, Matteo Astone, Ping Liu, Li Wang, Abbygail M. Coyle, Erin N. Dankert, Dane K. Hoffman, Stephanie R. Hall, Wei Zhang, Rui Kuang, Anja C. Roden, Aaron S. Mansfield, Luke H. Hoeppner. Molecular mechanisms of non-small cell lung cancer growth and drug resistance [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 873.